Vagisha Sharma

Vagisha Sharma


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
VSVagisha Sharma
Vagisha Sharma
SASiddharth Agarwal
Siddharth Agarwal
TGTanvi Mbbs Grover
Tanvi Mbbs Grover
AMAnureet Malhotra
Anureet Malhotra
Harendra KumarHarendra Kumar
Harendra Kumar
SSSatinder P. Md Singh
Satinder P. Md Singh
Coronary allograft vasculopathy, often known as cardiac allograft vasculopathy (CAV), is a substantial source of morbidity and mortality in people who have had heart transplants. Early detection and monitoring of CAV are crucial for improving outcomes in this population. Although cardiac computed tomography (CT) has emerged as a possible method for finding and evaluating CAV, invasive coronary angiography has long been thought of as the gold standard for recognizing CAV. This study focuses on the utility of cardiac CT for CAV diagnosis and treatment in the post-heart transplant population. It provides an overview of recent studies on the application of cardiac CT in CAV and highlights the advantages and disadvantages of this imaging modality. The potential application of cardiac CT for CAV risk assessment and care is also examined in the study. Overall, the data point to a potential role for cardiac CT in the detection and treatment of CAV in post-heart transplant patients. It enables evaluation of the whole coronary tree and low-radiation, high-resolution imaging of the coronary arteries. Hence, further study is required to determine how best to employ cardiac CT in treating CAV in this group.

5 June 2024 in Cureus
Verified
Journal Article
Open access
PDF file
PGPeter Girgis
Peter Girgis
TLTanisha Lnu
Tanisha Lnu
AAAmna Ahmad
Amna Ahmad
MDMina Daniel
Mina Daniel
MKMaria Kamel
Maria Kamel
VSVagisha Sharma
Vagisha Sharma
Crohn’s disease (CD) is a complex clinical condition characterized by persistent gastrointestinal inflammation that leads to episodes of flare-ups and subsequent healing. The treatment options for this disease are heterogeneous as its impact on different patients is also different. This study aims to evaluate the effectiveness of recently approved drugs that specifically target certain pathways within cells that are involved in CD pathogenesis. These medicines include biologics like anti-TNF agents, interleukin inhibitors, and small molecule inhibitors; they work by altering the modulation of immune responses and reducing inflammation. These drugs seem promising in terms of inducing remission in moderate to severe CD among various patient populations. Conversely, it is possible to examine how well these drugs perform using gene expression and molecular markers. By understanding these results along with other ongoing trials, personalized medicine can be used more frequently by doctors who will adopt a strategy for an individual patient, maximizing benefits while minimizing adverse effects. There are still some issues that need to be worked out like the high cost associated with these drugs or immunogenicity risk and infectious complications too. In conclusion, there has been a remarkable improvement in CD management over the past decade with customized drugs leading toward a precision medical era. Further understanding of molecular mechanisms implicated in CD pathogenesis and new therapeutic approaches could potentially improve treatment outcomes among affected individuals. This research is crucial in understanding how CD therapeutics are changing, thus facilitating selection by doctors on the most appropriate methods for individualized patient care.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
VSVagisha Sharma
Vagisha Sharma
KKKushal Kriplani
Kushal Kriplani
ITIsha Preet Tuli
Isha Preet Tuli
Mucormycosis is one of the most aggressive opportunistic fungal infections. Though conventionally limited to the demographics of immunocompromised and those on the diabetes spectrum. It has recently propelled to the frontline in investigations of COVID-19 complications. For patients present in varied stages and severity of Mucormycosis, it's crucial to discuss the presenting factors that impact mortality in order to provide more intensive care and treatment from the beginning to those more at risk of death. All patients presenting to a tertiary care hospital in New Delhi, India with clinicopathological confirmed Mucormycosis were enrolled in the study. Detailed history and physical examination were performed, and a questionnaire of patient demographic details and comorbidities was filled out. There were 75 patients who met the inclusion criteria and were assessed after obtaining informed consent. Of these 75, 64 patients survived. The most common comorbidity in the study population was Diabetes spectrum(89.33%), followed by antecedent COVID-19 infection(64%) and hypertension(12%). Despite a high prevalence, none of these was significantly associated with mortality. The only comorbidity associated with mortality was Coronary Artery Disease(p-value< 0.05). The symptomatology at presentation was also assessed. Most commonly reported symptoms at presentation were Orbital/facial edema(45.33%), nasal discharge(29.33%), nasal block(29.33%) and diminution of vision(26.66%). The presence of proptosis at presentation in the patient was found to be significantly associated with a mortality outcome(p-value< .0.05). The glycemic control at presentation was also measured and compared between the survivors and non-survivors, however, no significant association was found. Mucormycosis patients with presenting symptoms of proptosis should be prognosticated early and managed in the intensive care unit from the beginning due to the increased risk of mortality. Also, patients with coronary artery disease should be similarly given special attention and care due to the association with mortality. Other factors like antecedent COVID-19, diabetes, hypertension, tobacco and alcohol use and the extent of hyperglycemia do not impact patient outcome All Authors: No reported disclosures

30 June 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
VSVagisha Sharma
Vagisha Sharma
SRShiavax J. Rao
Shiavax J. Rao
GRGuy Rogers
Guy Rogers
SSSudhakar Sattur
Sudhakar Sattur
EKEdo Kaluski
Edo Kaluski

24 April 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
VSVagisha Sharma
Vagisha Sharma
PWPrima Wulandari
Prima Wulandari
AAAsna Aafreen
Asna Aafreen
YHYang Hao
Yang Hao
EKEdo Kaluski
Edo Kaluski

4 November 2023 in New Microbes and New Infections
Verified
Journal Article
Open access
Harendra KumarHarendra Kumar
Harendra Kumar
VSVagisha Sharma
Vagisha Sharma
BKBharat Kumar
Bharat Kumar
India and Pakistan share a common public health concern: rabies, which affects both humans and animals. Both countries have established national rabies control initiatives, but these programs face challenges such as inadequate funding and limited access to healthcare in rural areas. Non-governmental organizations (NGOs) are also working to control rabies in both India and Pakistan. Cross-Border Cooperation Crucial in Rabies Fight: SAARC Initiatives Promoting Regional Prevention. Crucial Steps: Raising Rabies Awareness and Accessible PEP in Both Countries.